Bayer AG. (8/30/18). "Press Release: Bayer Receives US Approval for Modern Hemophilia A Treatment Jivi with a Step-wise Prophylaxis Dosing Regimen [Not intended for U.S. and UK Media]". Berlin.

	Region	United States (USA)
	Organisation	Bayer AG
	Group	Bayer (Group)
	Organisation 2	FDA (US Food and Drug Administration)
	Group	United States (govt)
	Product	Jivi®
	Product 2	clinical research
	Person	Möller, Jörg (Bayer 201403 Bayer HealthCare Head of Global Development)

Original document
accessed by [iito] on 2018-09-04

Record changed: 2018-09-05

More documents for Bayer (Group)

[1] Bayer AG. (1/31/19). "Press Release: Bayer and Kyoto University Form Research Alliance to Discover New Treatment Approaches against Lung Diseases [Not intended for U.S. and UK Media]". Berlin....
[2] Dewpoint Therapeutics. (1/30/19). "Press Release: Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates". Cambridge, MA....
[3] Cyclica Inc.. (11/26/18). "Press Release: Cyclica Drives Drug Discovery through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer". Toronto....
[4] Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT....
[5] Compugen Ltd.. (11/7/18). "Press Release: Compugen Reports Third Quarter 2018 Results". Holon....
[6] Genedata AG. (9/27/18). "Press Release: Bayer Partners with Genedata to Digitalize Crop Science Research and Development". Basel....
[7] Celyad S.A.. (9/26/18). "Press Release: Celyad Appoints Carri Duncan as Vice-President Corporate Development and Communications". Mont-Saint-Guibert....
[8] Cellectis S.A.. (9/18/18). "Press Release: Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP". Minneapolis, MN & New York, NY....
[9] Sanofi S.A.. (9/13/18). "Press Release: Sanofi to Refocus Two Global Business Units". Paris....
[10] Bayer AG. (8/24/18). "Press Release: Bayer Secures Approval in the EU for Xarelto (rivaroxaban) for Patients with Coronary or Peripheral Artery Disease [Not intended for U.S. and UK Media]". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Bayer AG. (8/30/18). "Press Release: Bayer Receives US Approval for Modern Hemophilia A Treatment Jivi with a Step-wise Prophylaxis Dosing Regimen [Not intended for U.S. and UK Media]". Berlin.

More documents for Bayer (Group)